Pembrolizumab in Treating Patients With Intermediate or High-Risk Smoldering Multiple Myeloma
| 适应症 | Smoldering Plasma Cell Myeloma |
|---|---|
| 分期 | 早期1期 |
| 申办方 | M.D. Anderson Cancer Center |
| 状态 | 进行中（已停止招募） |
| 受试者人数 | 20 人 |
| 干预（药物） | Laboratory Biomarker Analysis, Pembrolizumab |
| 开始日期 | 2016年7月20日 |
| 完成日期 | 2017年12月30日 |
| 结果公布日 | 2020年3月20日 |
摘要
This pilot early phase I trial studies pembrolizumab in treating patients with slow growing (smoldering) multiple myeloma with intermediate or high-risk of spreading. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Overall Response Rate (ORR)
| Treatment (Pembrolizumab) | 1 Participants |
|---|
在 BENITIONS 中查看 查看 ClinicalTrials.gov 原文
同一适应症的其他试验
- Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Mu — National Cancer Institute (NCI)
- Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Tr — National Cancer Institute (NCI)
- Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previo — National Cancer Institute (NCI)
- Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment fo — University of Michigan Rogel Cancer Center
- Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) a — University of Alabama at Birmingham
- Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (M — National Cancer Institute (NCI)